Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism
CADTH
Record ID 32014000739
English
Authors' recommendations:
CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months. If treatment is to be extended beyond six months, the following condition must be met.
Condition: A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/SR0327_complete_Xarelto%20PEm_Mar-28-14.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Pulmonary Embolism
- Morpholines
- Thiophenes
- Anticoagulants
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.